Risk Factors for Lymphoma in Patients with Inflammatory Bowel Disease: A Case-control Study

被引:31
|
作者
Afif, Waqqas [1 ,2 ]
Sandborn, William J. [1 ,3 ]
Faubion, William A. [1 ]
Rahman, Meher [4 ]
Harmsen, Scott W. [5 ]
Zinsmeister, Alan R. [5 ]
Loftus, Edward V., Jr. [1 ]
机构
[1] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA
[2] McGill Univ, Div Gastroenterol & Hepatol, Ctr Hlth, Montreal, PQ, Canada
[3] Univ Calif San Diego, Div Gastroenterol & Hepatol, La Jolla, CA 92093 USA
[4] Mayo Clin Hlth Syst, Immanuel St Josephs Specialty Clin, Gastroenterol Sect, Mankato, MN USA
[5] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN 55905 USA
关键词
lymphoma; immunosuppressive; anti-TNF-alpha; EPSTEIN-BARR-VIRUS; CROHNS-DISEASE; LYMPHOPROLIFERATIVE DISORDERS; RHEUMATOID-ARTHRITIS; ULCERATIVE-COLITIS; AZATHIOPRINE; THERAPY; INFLIXIMAB; IMMUNOSUPPRESSION; 6-MERCAPTOPURINE;
D O I
10.1097/MIB.0b013e318281325e
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background:Subgroups of patients with inflammatory bowel disease (IBD) may have an increased risk of developing lymphoma. We sought to identify factors that were associated with lymphoma in patients with IBD.Methods:Cases and controls were identified through a centralized diagnostic index. We identified 80 adult patients with IBD who developed lymphoma between 1980 and 2009. For each case, 2 controls were matched for subtype of IBD, geographic location, and length of follow-up. Conditional logistical regression was used to assess associations between risk factors and the development of lymphoma.Results:Sixty patients were males (75%) versus 77 controls (48%). Median age at index date was 59 years for cases and 42 years for controls. Twenty patients (25%) and 23 controls (14%) were receiving immunosuppressive medications at the index date. Four patients (5%) and 6 controls (4%) were receiving anti-tumor necrosis factor agents at the index date. In multiple variable analysis, age per decade (odds ratio, 1.83; 95% confidence interval, 1.37-2.43), male gender (odds ratio, 4.05; 95% confidence interval, 1.82-9.02) and immunosuppressive exposure at the index date (odds ratio, 4.20; 95% confidence interval, 1.35-13.11) were significantly associated with increased odds of developing lymphoma. Disease severity and use of anti-tumor necrosis factor agents were not independently associated with developing lymphoma. When testing was performed on patients exposed to immunosuppressive or anti-tumor necrosis factor medications, Epstein-Barr virus was identified 75% of the time.Conclusions:In this case-control study, increasing age, male gender, and use of immunosuppressive medications were associated with an increased risk of lymphoma in patients with IBD.
引用
下载
收藏
页码:1384 / 1389
页数:6
相关论文
共 50 条
  • [31] Isotretinoin Use and the Risk of Inflammatory Bowel Disease: A Case-Control Study
    Crockett, Seth D.
    Porter, Carol Q.
    Martin, Christopher F.
    Sandler, Robert S.
    Kappelman, Michael D.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 (09): : 1986 - 1993
  • [32] Risk of Inflammatory Bowel Disease From Isotretinoin: A Case-Control Study
    Sivaraman, Susil
    Rashtak, Shahrooz
    Sivaraman, Susanth
    Scherr, Rebecca
    Baron, Howard
    Stone, Christian
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S506 - S506
  • [33] Active tuberculosis in inflammatory bowel disease patients: a case-control study
    de Azevedo, Matheus Freitas Cardoso
    Barros, Luisa Leite
    Justus, Filipe Fernandes
    Oba, Jane
    Garcia, Karoline Soares
    Martins, Camilla de Almeida
    Carlos, Alexandre de Sousa
    Leite, Andre Zonetti Arruda
    Sipahi, Aytan Miranda
    Queiroz, Natalia Sousa Freitas
    Damiao, Aderson Omar Mourao Cintra
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2023, 16
  • [34] Active tuberculosis in inflammatory bowel disease patients: a case-control study
    de Azevedo, Matheus Freitas Cardoso
    Barros, Luisa Leite
    Justus, Filipe Fernandes
    Oba, Jane
    Garcia, Karoline Soares
    Martins, Camilla de Almeida
    Carlos, Alexandre de Sousa
    Leite, Andre Zonetti Arruda
    Sipahi, Aytan Miranda
    Queiroz, Natalia Sousa Freitas
    Damiao, Aderson Omar Mourao Cintra
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2023, 16
  • [35] Risk factors for opportunistic infections in inflammatory bowel diseases: A case-control study
    Toruner, Murat
    Loftus, Edward V.
    Colombel, Jean F.
    Orenstein, Robert
    Harmsen, W. S.
    Zinsmeister, Alan R.
    Sandborn, William J.
    Egan, Laurence J.
    GASTROENTEROLOGY, 2006, 130 (04) : A71 - A71
  • [36] Prevalence and Risk Factors of Anemia in Inflammatory Bowel Diseases: A Case-Control Study
    Aslam, Tahir
    Mehmood, Asim
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (07)
  • [37] A case control study on the risk factors of inflammatory bowel disease in China
    Wang, Y. F.
    Ouyang, Q.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 : 130 - 130
  • [38] Inflammatory Bowel Disease Environmental Risk Factors: A Case-Control Study of the Middle Eastern Migrant Population
    Ko, Yanna
    Karnib, Mohamad
    Rahme, Nabil
    Alrubaie, Ahmad
    McDonald, Charles
    Katelaris, Peter
    Jones, D. Brian
    Samuel, Douglas
    Leong, Rupert W.
    GASTROENTEROLOGY, 2013, 144 (05) : S647 - S647
  • [39] Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study
    Losurdo, Giuseppe
    La Fortezza, Rosa Federica
    Iannone, Andrea
    Contaldo, Antonella
    Barone, Michele
    Ierardi, Enzo
    Di Leo, Alfredo
    Principi, Mariabeatrice
    WORLD JOURNAL OF GASTROENTEROLOGY, 2020, 26 (47) : 7528 - 7537
  • [40] Inflammatory bowel disease environmental risk factors: A case-control study of the middle eastern migrant population
    Ko, Y.
    Karnib, M.
    Samuels, D.
    Alrubaie, A.
    Rahme, N.
    Mcdonald, C.
    Cowlinshaw, J.
    Katelaris, P.
    Barr, G.
    Jones, B.
    Leong, R.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 110 - 111